Specific adverse events · adults with episodic tension‐type headache
1 finding from 1 review
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
Total mortalitya · hypotensive shock
Dopamine showed no clear difference in total mortalitya compared with norepinephrine (high certainty).
1 finding from 1 review
Arrhythmias · hypotensive shock
Dopamine leads to higher arrhythmia < BR/> compared with norepinephrine (high certainty).
1 finding from 1 review
Total mortalitya · hypotensive shock
It is very uncertain whether terlipressin changes total mortalitya compared with norepinephrine (very low certainty).
1 finding from 1 review
Total mortalitya · hypotensive shock
Vasopressin showed no clear difference in total mortalitya compared with norepinephrine (moderate certainty).
1 finding from 1 review
Total mortalitya · hypotensive shock
It is very uncertain whether phenylephrine changes total mortalitya compared with norepinephrine (very low certainty).
1 finding from 1 review
Total mortalitya · hypotensive shock
Epinephrine showed no clear difference in total mortalitya compared with norepinephrine (low certainty).
1 finding from 1 review
Intervention not reported
End of treatment SBP (over 12 weeks) · patients with primary hypertension
1 finding from 1 review
Intervention not reported
End of treatment DBP (over 12 weeks) · patients with primary hypertension
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse effects · patients with primary hypertension
1 finding from 1 review
Intervention not reported
Systolic blood pressure · People with primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic blood pressure · People with primary hypertension
1 finding from 1 review
Intervention not reported
Heart rate · People with primary hypertension
1 finding from 1 review
Intervention not reported
Pulse pressure · People with primary hypertension
1 finding from 1 review
Intervention not reported
WDAE · People with primary hypertension
1 finding from 1 review
Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether thrombopoietin mimetics changes number of participants with at least 1 bleeding episode compared with placebo or standard care (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with severe or life‐threatening bleeding · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether the intervention changes number of participants with severe or life‐threatening bleeding (very low certainty).
1 finding from 1 review
Intervention not reported
Number of days on which bleeding occurred ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Time from randomisation to first bleeding episode ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found